Skip to main content
Makers Laboratories Ltd. logo

Makers Laboratories Ltd. — Investor Relations & Filings

Ticker · 506919 ISIN · INE987A01010 LEI · 3358003XJ6DLKIEJCG14 BSE.NS Manufacturing
Open in API
Filings indexed 355 across all filing types
Latest filing 2026-05-27 Report Publication Anno…
Country IN India
Listing BSE.NS 506919

About Makers Laboratories Ltd.

https://www.makerslabs.com/

Makers Laboratories Ltd. specializes in the manufacturing and marketing of a broad spectrum of pharmaceutical formulations. The company’s product range covers multiple therapeutic areas, including anti-malarials, ophthalmics, anti-diabetics, cardiovascular, and gastrointestinal health. Its manufacturing capabilities encompass various dosage forms such as tablets, capsules, oral liquids, and topicals. The company focuses on delivering high-quality generic medicines and maintains specialized marketing divisions to cater to diverse medical needs. By leveraging established manufacturing processes and quality control systems, the company aims to provide accessible healthcare solutions across its target therapeutic segments.

Recent filings

Filing Released Lang Actions
Copy of Newspaper Publication
Report Publication Announcement Classification · 85% confidence The opening section is a letter to BSE under SEBI LODR Regulation 47 stating that audited financial results have been published in newspapers and copies are enclosed. It does not include a full Annual Report or Interim Report narrative/MD&A, nor is it a simple earnings highlight—rather it announces that the report has been published and provides the extracts. Under the “menu vs meal” rule, this is a Report Publication Announcement (RPA) rather than the report itself.
2026-05-27 English
Annual Secretarial Compliance Report for the period ended 31st March, 2026.
Regulatory Filings Classification · 92% confidence The document is a Secretarial Compliance Report and accompanying certificate under Regulation 24A of SEBI LODR filed with the stock exchange. It is an officer certification/compliance attestation, not an annual financial report or management presentation, and contains no substantive financial statements. Under the Certification Rule and fallback hierarchy, it should be classified as a general regulatory filing (RNS).
2026-05-27 English
Standalone and Consolidated Results for FY 25-26
Regulatory Filings Classification · 75% confidence The document is a mandatory SEBI (Listing Obligations and Disclosure Requirements) Regulation 33 filing to BSE Ltd. It contains the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026, along with the Independent Auditor’s Report and related statutory disclosures. It is not a full narrative Annual Report (10-K), nor merely a highlights-only Earnings Release (ER) or an interim/quarterly report (IR) in isolation. Instead, it is a regulatory compliance announcement of audited results under listing regulations. As such, it falls under the general Regulatory Filings (RNS) category.
2026-05-26 English
Standalone and Consolidated Financial Results for FY 25-26
Audit Report / Information Classification · 80% confidence The document is an official filing under SEBI Regulation 33 by Makers Laboratories Limited containing: (i) the Audited Standalone Financial Results for the quarter and financial year ended March 31, 2026, (ii) the Auditors’ Reports on those results, and (iii) full financial statements (Income Statement, Balance Sheet, Cash Flow, and Notes). It is not a short earnings summary (ER) nor merely an announcement of a report (RPA) – the actual audited figures and the auditor’s opinion are included. It is not a full Annual Report (10-K) with MD&A, but it does include the standalone audit report and audited financials. Therefore, it falls under “Audit Report / Information” (AR). FY 2026
2026-05-26 English
Makers Laboratories Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....
Regulatory Filings Classification · 80% confidence The document is a notice under SEBI Regulation 29 to the stock exchange announcing a Board meeting date for considering and taking on record the audited financial results. It does not contain the financial results themselves, nor is it a management change or dividend notice. It is a regulatory compliance announcement rather than the report itself or its publication with attachments. Therefore, it best fits the catch-all Regulatory Filings (RNS) category.
2026-05-05 English
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2026.
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended March 31, 2026. It is a compliance certificate issued by the Registrar and Share Transfer Agent to the company and filed with the stock exchange. The document is short (3091 characters) and primarily serves as a regulatory compliance confirmation rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of a report but a certificate confirming regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance certificates and regulatory confirmations.
2026-04-06 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.